IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?

This review discusses immunomodulatory drug (IMiDs) sequencing and IMiD-free interval strategies for lenalidomide-refractory myeloma. IMiDs and proteasome inhibitors (PIs) improve clinical outcomes in patients with myeloma; however, refractoriness to lenalidomide, a category of IMiD, predicts poor o...

Full description

Bibliographic Details
Main Authors: Kazuhito Suzuki, Shingo Yano
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Life
Subjects:
multiple myeloma
immunomodulatory drug
proteasome inhibitor
anit-CD38 monoclonal antibody
lenalidomide-refractory
Online Access:https://www.mdpi.com/2075-1729/13/11/2229

Internet

https://www.mdpi.com/2075-1729/13/11/2229

Similar Items